- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.01. | Avacta expands peptide-drug conjugate study after seeing 10% response rate | ||
| 15.01. | JPM25: GE HealthCare, UCSF launch research hub for cancer, neurodegenerative disease imaging | ||
| 15.01. | OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients | ||
| 15.01. | Neumora's dig into phase 3 depression data disappoints analysts | ||
| 15.01. | FDA elevates Philips cardiac telemetry recall over unflagged ECG alerts, following 2 deaths | ||
| 15.01. | Keros, after halting 2 cohorts over fluid buildups around heart, pulls plug on hypertension trial | ||
| 15.01. | JPM25, Day 3: GSK's liver disease plans, the Biotech CEO Sisterhood, and more | ||
| 15.01. | JPM25: GSK's CSO shares science strategy behind deal-making, plus plans to build off GLP-1s-but not for obesity | ||
| 14.01. | Daiichi Sankyo gins up antibody research project with German research institute | ||
| 14.01. | N-Power links up with Synapse to add oncologists to clinical research network | ||
| 14.01. | JPM25: Dexcom predicts 2025 growth, with Stelo pushing portfolio updates | ||
| 14.01. | Umoja secures $100M series C to bring more CAR-Ts into the clinic | ||
| 14.01. | Sling's oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3 | ||
| 14.01. | RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront | ||
| 14.01. | JPM25, Day 2: Trump admin health picks 'like a box of chocolates' | ||
| 13.01. | JPM25: Roche has access to $10B in M&A firepower per year, pharma CEO says. Where will it spend the money? | ||
| 13.01. | JPM25: AbbVie pens $1B deal for Simcere's phase 1 T-cell engager | ||
| 13.01. | Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial | ||
| 13.01. | JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project | ||
| 13.01. | JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale | ||
| 13.01. | JPM25: Guardant Health posts 31% sales gain as cancer blood tests expand | ||
| 13.01. | Telix continues shopping spree with $45M purchase of ImaginAb's preclinical drugs, facility | ||
| 13.01. | Blueprint ends work on clinical-stage CDK2 inhibitor but pushes on in breast cancer | ||
| 13.01. | Epigenetic biotech raises bumper round to the Tune of $175M to fund entry into clinic | ||
| 11.01. | Obesity-focused Metsera files IPO just nine months after emerging |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
